AARTI DRUGS LTD. - 524348 - Compliance Certificate For Year Ended March 31, 2022
Compliance Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201506-04-2022
06-04-2022
AARTI DRUGS LTD. - 524348 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Rushikesh DeoleDesignation :- Company Secretary and Compliance Officer05-04-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Retirement
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure requirements), Regulations, 2015, we wish to inform that Shri Bhavesh R. Vora (DIN: 00267604) and Shri Vilas G. Gaikar (DIN: 00033383), Independent Directors have retired from the Board of Directors of the Company, with effect from close of business hours on March 31, 2022, after the cessation of their tenure pursuant to Section 149(11) of the Companies Act, 2013.02-04-2022
AARTI DRUGS LTD. - 524348 - Closure of Trading Window
This is to inform that the Trading Window of the Company will remain closed from April 1, 2022 until the expiry of 48 hours after the declaration of Financial Results of the Company for the quarter and year ended March 31, 2022.31-03-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) as per the details below.29-03-2022
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates29-03-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) as per the details below.24-03-2022
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates25-02-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) as per the details below.16-02-2022
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be attending the Investor Conference10-02-2022